A panel of experts voted in support of four tools for collecting patient-reported outcomes that Medicare could factor into payment decisions for costly CAR-T cancer drugs.
Medscape Medical News
Original Article: CMS Advisers Back Patient Reporting Tools for CAR-T Drugs